{
    "nct_id": "NCT04685616",
    "official_title": "A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma",
    "inclusion_criteria": "* Males and females aged 16-69 years (inclusive) (age range is 18-69 in US and EU)\n* Histologically confirmed classical Hodgkin lymphoma\n* Stage I or II supradiaphragmatic disease with no mediastinal bulk disease (defined as greater than a third of the transthoracic diameter at any level of thoracic vertebra as determined by CT) or B symptoms. Bulky disease at other sites is acceptable. Extranodal disease (single extranodal site (stage I) or contiguous nodal extension (stage II)) is acceptable.\n* ECOG performance status 0-2.\n* No previous treatment for Hodgkin lymphoma\n* Fit to receive anthracycline-based chemotherapy (patients with a history of ischaemic heart disease or hypertension should have a left ventricular ejection fraction of ≥50%)\n* Creatinine clearance (measured or calculated >40ml/min\n* Total bilirubin <1.5 x upper limit of normal, unless attributable to disease or known Gilbert's syndrome\n* ALT or AST < 2 x upper limit of normal\n* Adequate bone marrow function with neutrophils ≥1.0x10^9/l and platelets ≥100x10^9/l\n* Haemoglobin ≥8g/dL\n* Willing and able to comply with the requirements of the protocol, including contraceptive advice, where applicable\n* Written informed consent\nHealthy volunteers allowed\nMust have minimum age of 16 Years\nMust have maximum age of 69 Years",
    "exclusion_criteria": "* Previous treatment for Hodgkin lymphoma, excluding short courses of oral corticosteroids at a dose of 100mg prednisolone (or equivalent) for up to 7 days\n* Infradiaphragmatic disease\n* Nodular lymphocyte predominant Hodgkin lymphoma\n* Absence of FDG-avid lesions on baseline PET scan\n* Age 70 years or over or age 15 years or under\n* Other cancer diagnosed with the last 5 years. Patients with completely excised carcinoma in situ of any type and basal or squamous cell carcinoma of the skin are not excluded\n* Recurrent or persistent other cancer within last 5 years irrespective of date of initial diagnosis\n* Pre-existing grade ≥1 sensory or motor neuropathy from any cause\n* History of or current progressive multi-focal leukoencephalopathy or other chronic condition of the brain\n* Symptomatic neurologic disease compromising normal activities of daily living or requiring medications\n* Infection with HIV, hepatitis C or active hepatitis B infection (surface antigen or DNA positive)\n* Any active systemic viral, bacterial or fungal infection requiring systemic antibiotics, antivirals or antifungals within 2 weeks prior to first trial drug dose\n* Receiving or recently treated with any other investigational agent (within 4 weeks of trial entry)\n* Pregnant or breastfeeding women\n* Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin or any component of ABVD\n* Known history of any cardiovascular or respiratory conditions that would preclude anthracycline or bleomycin administration\n* Other significant medical or psychiatric comorbidity that in the opinion of the investigator would make administration of ABVD or A2VD hazardous",
    "miscellaneous_criteria": ""
}